Clinical trial · Observational
The Role of tHyroid cAncer Specific Patient Concerns iNventory (PCI-TC) in Enhancing Shared decisiOn Making
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multiple clinical equipoises exist for the management of thyroid cancers. Shared decision-making (SDM) process where patients are supported to consider options, to achieve informed preferences with their clinicians have been recommended to improve patients' satisfaction and their overall quality of life. However, SDM can be difficult to achieve in our standard clinical encounters due to clinician's lack of confidence and time limitation to elicit patient's concerns and preferences. PCI as a decision-making support tool has shown to enhances clinician's awareness of patient's needs and allows for a more effective communication while the consultation time is unaffected. The successful development, testing and implementation of a PCI-TC could improve patient satisfaction, clinical efficiency and ensure that unmet need is appropriately addressed. This study will support the development of PCI-TC to better understand the wide-ranging needs of our patients and to improve the SDM process in the thyroid cancer management pathway.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- No use of PCI-TC in clinical consultations
- description
- In this phase we aim to explore the views of the current decision-making process in thyroid cancer treatment. The patients will be approached for interview within 14 days after their consultations where the treatment decisions for their low risk differentiated thyroid cancer are made. There is no time restriction to approach clinicians for interview.
- interventionNames
- Other: Interview
- label
- User experience of PCI-TC in thyroid cancer outpatient clinic setting
- description
- First, the clinicians will be trained on how to use the PCI-TC in their outpatient clinics. A new group of patients will then be identified and recruited for the phase two study. Patients from this new group will be given the PCI-TC in a quiet area just off the waiting area prior to the consultation. They will be asked to tick items on the PCI-TC list which they wish to discuss. The clinicians will conduct the consultation using the ticked PCI-TC as a guide and discuss with patients regarding the treatment plan for their thyroid cancer. The patients will be approached for interview within 14 days after their consultations. The clinicians will be approached for interview after all recruited patients in phase two study have had their consultation regarding their cancer treatment.
- interventionNames
- Other: Interview
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged over 18 * Both genders * Patients who are diagnosed of low-risk well-differentiated thyroid carcinoma (papillary thyroid carcinoma or follicular carcinoma) with size of 1-4cm. This is either: 1. Diagnosed pre-operatively by fine-needle aspiration cytology (FNAC) with Thy5 grade \[see appendix for the Thy classification\] or 2. Confirmed following diagnostic hemithyroidectomy * Able to communicate in spoken and written English Inclusion criteria for clinician participants * Consultant head and neck and thyroid surgeons who directly involve in the diagnosis and/or management of low-risk well-differentiated thyroid cancer (papillary thyroid carcinoma or follicular carcinoma) with size of 1-4cm for at least ten patients per year. * Both genders * Able to communicate in spoken and written English Exclusion Criteria: * Patients who are diagnosed with tumour with adverse features this includes: * Tumour with poor differentiated cytology or variants with bad prognosis (tall cell, columnar cell, Hurthle cell, solid variant) * Tumour, which is multifocal, bilateral, with extrathyroidal extension, with perineural or lymphovascular invasion. * Tumour with clinically or radiologically involved nodes or distant metastases * Tumour which is of a familial disease * Patient who is either Pregnant or breast-feeding * Patient with hyper- or hypothyroidism who is a candidate for surgery * Patient who is concurrently diagnosed with any medullary, anaplastic, lymphoma, or parathyroid disease * Patients who had previous thyroidectomy for reasons other than diagnostic hemithyroidectomy for their recent cancer diagnosis. * Patients who are cognitively impaired or have a mental health condition and are therefore unable to give consent * Patient who is not able to read write and speak English. Exclusion criteria for clinician participants • Consultant surgeons who diagnose and/or manage low-risk well-differentiated thyroid cancer for less than ten patients per year.
References
Publications (0)
Data not yet available